ArticleJournal of cardiovascular development and disease2025
Prognostic Role of Pan-Immune-Inflammatory Value in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.
Article in Journal of cardiovascular development and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pan-immune-inflammation value for risk stratification of adverse cardiovascular outcomes in acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Comparative Prognostic Performance of Platelet-Containing and Platelet-Free Inflammatory Indices After Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Article
- Association of the Pan-Immune-Inflammation Value-to-Albumin Ratio as a Novel Cardiovascular Disease Predictor in Type 2 Diabetes: A Prospective Cohort Study.Biomedicines · 2026Article
- Prognostic Value of the Cumulative Inflammatory Index (IIC) in Patients with Non-ST-Segment Elevation Myocardial Infarction.Biomedicines · 2026Article
- Effect of Perfluorooctanesulfonic Acid on Fibrin Clot Properties and Thrombin Generation: Linking Environmental Pollution with Cardiovascular Diseases.Journal of cardiovascular development and disease · 2026Article
- The Clinical Significance and Prognostic Value of Inflammatory Hematological Indices in Young Patients with Coronary Artery Disease.Journal of inflammation research · 2026Article
- Prediction model for postoperative acute kidney injury in non-cardiac surgical patients: a retrospective cohort study.BMC nephrology · 2025Article
- Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker.Medical sciences (Basel, Switzerland) · 2025Article
- The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus: a prospective cross-sectional study.BMC endocrine disorders · 2025Article
- A New Perspective on NSTE-ACS Patients in the Emergency Department: Cardiac Risk Prediction with New Inflammation Markers.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood cell-derived indices are potential predictors of clinical outcomes in coronary artery disease. This study assessed the prognostic value of the pan-immune-inflammatory value (PIV) for predicting 1-year major adverse cardiovascular events (MACEs) in patients with non-ST-segment elevation acute coronary syndrome (ACS). A retrospective cohort of 1651 patients receiving percutaneous coronary intervention was analyzed. PIV, calculated from blood cell counts, was categorized with a cut-off value of 256.3 (sensitivity 60.7%, specificity 59.3%) based on receiver operating characteristic curve analysis. MACEs were operationalized as a composite of all-cause mortality, myocardial infarction (MI), stroke, any revascularization, and rehospitalization for heart failure. The incidence of MACEs was 5.0% in patients with low PIV and 9.7% in those with high PIV (log-rank
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.